Phase 3 Type 2 Diabetes Trial, Recruiting NCT06716216 Sponsor: BrightGene Bio-Medical Technology Co., Ltd. Condition: Type 2 Diabetes
Back to Type 2 Diabetes

Phase 3 Type 2 Diabetes Trial, Recruiting

NCT06716216
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed with type 2 diabetes.
  • People who are taking metformin, either at a stable dose of 1500 mg per day or more, at the highest dose they can tolerate (between 1000 mg and less than 1500 mg per day), or combined with a stable dose of a sulfonylurea medication for at least 8 weeks before the study starts (confirm with trial site for which category applies).
  • People with a Body Mass Index (BMI) of 23 or above at the time of screening.
  • People whose weight has been stable (within plus or minus 5%) for at least 3 months before the screening visit.
  • People whose HbA1c blood sugar level is between 7.5% and 11.0% (a measure of average blood sugar over roughly 3 months).

Who may not be able to join:

  • People who have been diagnosed with type 1 diabetes or certain other specific types of diabetes.
  • People who have had a cancer diagnosis in the past 5 years, or where cancer is suspected, with some exceptions for certain early-stage or fully treated skin, cervical, prostate, or thyroid cancers with no recurrence after surgery (confirm with trial site).
  • People who have ever had chronic or acute pancreatitis (inflammation of the pancreas).
  • People who have a known history of multiple allergies (to 3 or more foods or medicines), an allergy to a class of diabetes medications called GLP-1 receptor agonists, or severe allergic conditions such as asthma, hives, or eczema-related skin inflammation.
  • People who are not able to make decisions for themselves or who have significant difficulty communicating.
  • People with a known or suspected history of alcohol or drug misuse.
  • People who are pregnant or currently breastfeeding.
  • People whom the trial doctor considers unsuitable for any other reason.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 12 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +86 13910978815

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
BrightGene Bio-Medical Technology Co., Ltd.
Registry
ClinicalTrials.gov
Start date
29 November 2024
Est. completion
20 March 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Change From Baseline in Hemoglobin A1c (HbA1c)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 12 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov